Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.
about
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaborationCurrent perspectives on HIV-1 antiretroviral drug resistancePairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease.Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA.The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbonesMutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsComparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.In Vivo validation of a bioinformatics based tool to identify reduced replication capacity in HIV-1.Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection.Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTClinical significance of human immunodeficiency virus type 1 replication fitness.Novel enzyme-linked minisequence assay for genotypic analysis of human immunodeficiency virus type 1 drug resistance.Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs.Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatmentsParameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants.Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assayN88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.Rapid propagation of low-fitness drug-resistant mutants of human immunodeficiency virus type 1 by a streptococcal metabolite sparsomycin.
P2860
Q24656978-82AF2CC1-4C51-47C2-A95E-874E5348F40AQ24792432-5EEB4417-7693-4F31-80F6-2523F6408231Q26852626-953B3FEC-6EA5-4286-9EC8-F52E4AEF493DQ33503921-92117E74-8290-40A1-954E-0AC07A78F397Q33513336-68020B7B-9A30-4EB4-8576-A293D43220D4Q33872810-2A71239E-B72D-4902-9CBE-D65E84AB5C82Q33935276-DF129CA9-BE99-4105-BCC4-9B1FAC8B2ED9Q34140913-38154B0B-4E0E-4BC0-94E9-D316B15B6AC3Q34280466-80FE4C29-87A7-495E-9675-46D14AD6DA04Q34489239-D7D40615-C30E-4488-9295-41C6FABFE0F9Q34991044-00651EEE-6E8F-4832-9A78-285B8F952D58Q35300021-F089D04B-612B-4A85-8D41-15A4933250B8Q35542741-1135FA51-8C8D-45F0-9C4A-F4F7766A78AFQ35548279-E146F8CF-5142-4CA6-B2D3-8A3B6044C59FQ36900010-AE5263DC-A2DF-4DA0-A035-C127D81F3D7DQ36969857-CC5AB120-1843-4840-BC5D-0E3E568E5F15Q37058422-02E1C5B6-AD02-4B18-BDB8-E6ED62018056Q39689383-2ABF00A4-4CBE-4BF8-A8B4-D4AE7722D512Q39741937-4568D20D-422C-47D7-9053-83BDA45007E0Q39996438-A4AF9387-F893-4C9D-B496-A7F167518D86Q40909665-7BF24F1A-DB57-47A7-8833-3D2641CBE8FAQ43250924-D554D748-567C-4AE3-A864-80F4D418A262Q44282743-32ACEFBB-2037-4569-B28B-E028FD74004BQ45410662-BD74DA94-8E8E-44B1-BF24-54654096675A
P2860
Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Interference between D30N and ...... immunodeficiency virus type 1.
@ast
Interference between D30N and ...... immunodeficiency virus type 1.
@en
Interference between D30N and ...... immunodeficiency virus type 1.
@nl
type
label
Interference between D30N and ...... immunodeficiency virus type 1.
@ast
Interference between D30N and ...... immunodeficiency virus type 1.
@en
Interference between D30N and ...... immunodeficiency virus type 1.
@nl
prefLabel
Interference between D30N and ...... immunodeficiency virus type 1.
@ast
Interference between D30N and ...... immunodeficiency virus type 1.
@en
Interference between D30N and ...... immunodeficiency virus type 1.
@nl
P2093
P2860
P1476
Interference between D30N and ...... immunodeficiency virus type 1.
@en
P2093
Aiko Okano
Brendan Larder
Hanae Abumi
Hiroshi Yoshikura
Kaneo Yamada
Kurt Hertogs
Masakazu Matsuda
Masashi Tatsumi
Noboru Takata
Satoshi Shirahata
P2860
P304
P356
10.1128/AAC.46.3.708-715.2002
P407
P577
2002-03-01T00:00:00Z